SeqOne, a leader in AI-driven genomic analysis, has announced its acquisition of Congenica, a UK company from the Wellcome Sanger Institute. This merger establishes one of the most significant global pure-play software companies in genomics, serving over 160 laboratories in more than 30 countries.
Founded in 2012, Congenica brings extensive clinical expertise, having partnered with over 25 laboratories, including NHS Genomics Laboratory Hubs and prominent programs such as Genomics England and the Hong Kong Genomic Program.
SeqOne’s AI-powered platform offers clinical decision-support tools for rapid and accurate analysis of genetic data in oncology, rare diseases, and infectious diseases. The integration of SeqOne’s platform with Congenica’s decision-support technology will facilitate rapid, actionable insights, speeding up diagnoses for rare diseases and enhancing personalized cancer therapies.
As sequencing costs shrink, the challenge for labs has shifted from data generation to interpretation—a bottleneck that can be addressed with advanced software.
This acquisition follows SeqOne’s impressive growth, doubling revenue and expanding from three to over 30 countries in a year. With more than 125 workers, the combined entity aims to achieve over 200,000 patient genomic analyses by 2025. SeqOne is committed to maintaining continuity of service for Congenica customers while expanding their product offerings with a significant UK presence at the Wellcome Sanger Institute.
KEY QUOTES:
“The rapid pace of personalized medicine demands continuous investment in software innovation and deep specialization. By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project.”
Martin Dubuc, CEO of SeqOne
“Congenica has been an instrumental partner to Genomics England, particularly in advancing rare disease diagnosis through their robust platform for clinical whole genome analysis. We look forward to continuing this important work with the combined expertise of the SeqOne team to deliver benefits for patients.”
Dr. Richard Scott, Chief Executive Officer at Genomics England
“The Board of Congenica is proud of the immense impact our technology has had on healthcare since our inception. We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”
Dr Andy Richards CBE, Chairman of Congenica
